Biosimilar Coding Policy For Medicare Reversed To 'Promote Innovation'
Executive Summary
Decision reflects Trump Administration's willingness to reconsider past efforts at cost control to address biopharma industry's concerns.
You may also be interested in...
Medicare Part D Rule Offers Modest Drug Price Savings, No Point-of-Sale Rebates
CMS Administrator Verma declined to suggest a timeframe for when such a policy redirecting negotiated drug rebates to offset cost sharing in Medicare Part D might be implemented.
Part D Plan To Adjust Cost Sharing For Biosimilars Questioned By PhRMA
PhRMA suggests that treating biosimilars like generics in some cases could lead to confusion and may have little impact on cost sharing for beneficiaries.
Part D Plan To Adjust Cost Sharing For Biosimilars Questioned By PhRMA
PhRMA suggests that treating biosimilars like generics in some cases could lead to confusion and may have little impact on cost sharing for beneficiaries.